To assess the efficacy of Avastin injection in treatment of pterygium

To assess the efficacy of sub-conjunctival Bevacizumab (Avastin) injection in treatment of primary fleshy pterygium (based on TAN grading) in patients with bilateral primary fleshy pterygium in comparison with sham injection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014092819319N1

Enrollment

Registered

2015-01-24

Start date

2013-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pterygium. PTERYGIUM

Interventions

Intervention 1: Intervention 1: Using a 1-ml syringe with 30-gauge needle, 2.5 mg (0.1 ml) of bevacizumab will be injected to the subconjunctival area of pterygium body only once. Intervention 2:

Treatment - Drugs

Placebo

Intervention 1: Using a 1-ml syringe with 30-gauge needle, 2.5 mg (0.1 ml) of bevacizumab will be injected to the subconjunctival area of pterygium body only once.

The intervention No. 2: Sham injection will be done for the other eye of the same patient only once.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with 20 to 70 years old, with primary bilateral fleshy pterygium invading between 1 to 4 mm into the cornea. Exclusion criteria: Any evidence of cancer or other ocular diseases except refraction errors (including anterior segment and posterior segment), diabetic patients and pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TAN grading. Timepoint: After one month, three months and six months . Method of measurement: based on the visibility of the underlying episcleral blood vessels in slit-lamp examination (questionnaire).;Mean pterygium size. Timepoint: After one month, three months and six months. Method of measurement: Millimeter(By slit-lamp).;Photophobia. Timepoint: After one month, three months and six months. Method of measurement: Questionnaire.;Mean surface area of pterygium. Timepoint: After one month, three months and six months. Method of measurement: Square millimeters(By slit-lamp).;Hyperemia. Timepoint: After one month, three months and six months. Method of measurement: Questionnaire.;Keratometry. Timepoint: After one month and six months. Method of measurement: By keratometer device.;Best corrected visual acuity. Timepoint: After one month, three months and six months. Method of measurement: Snellen -E-chart.;Clinical symptoms (tingling, itching, redness, epiphora). Timepoint: After one week, one month, three months and six months. Method of measurement: Questionnaire.	—

Measure

Time frame

TAN grading. Timepoint: After one month, three months and six months . Method of measurement: based on the visibility of the underlying episcleral blood vessels in slit-lamp examination (questionnaire).;Mean pterygium size. Timepoint: After one month, three months and six months. Method of measurement: Millimeter(By slit-lamp).;Photophobia. Timepoint: After one month, three months and six months. Method of measurement: Questionnaire.;Mean surface area of pterygium. Timepoint: After one month, three months and six months. Method of measurement: Square millimeters(By slit-lamp).;Hyperemia. Timepoint: After one month, three months and six months. Method of measurement: Questionnaire.;Keratometry. Timepoint: After one month and six months. Method of measurement: By keratometer device.;Best corrected visual acuity. Timepoint: After one month, three months and six months. Method of measurement: Snellen -E-chart.;Clinical symptoms (tingling, itching, redness, epiphora). Timepoint: After one week, one month, three months and six months. Method of measurement: Questionnaire.

—

Secondary

Measure	Time frame
Complications for example;infection and hemorrhage. Timepoint: After one week, one month, three months and six months. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Haghi

Iran University of Medical Science

Alireza_Haghi1389@yahoo.com+98 21 6435 2473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026